Category Archives: Cannabis
As it stands today, cannabis is a Schedule I narcotic, on the same US government list as heroin, ecstasy and other illicit drugs deemed to have high abuse potential. For 28 states and the District of Columbia where cannabis is legal for medical and/or recreational adult use, this is a huge problem, especially for state agencies and laboratories tasked with regulatory oversight and public health surveillance of cannabis safety.
Here are just a few of this issue’s highlights:
- The PATH to Improved Hormone Testing
- 15 Minutes with John Auerbach
- Expanding State Newborn Screening Panels in Missouri and Iowa
- Kenya Launches National Equipment Calibration Center
- The Best Defense: Routine Public Health Testing
- Colorado Puts Cannabis Testing on High Priority
- Moving Up or Moving On: Career Advancement and Workplace Satisfaction in State PHLs
The post New Lab Matters: Cannabis testing and public health laboratories appeared first on APHL Lab Blog.
By Shawn Kassner, senior scientist, Neptune and Company, Inc.
Over the past few years, we have seen many states legalize medical and recreational cannabis. Legalization of medical cannabis, in particular, has generated increased awareness of the many health issues that cannabis and cannabis-based products are used to treat. Pediatric seizure disorders, post-traumatic stress syndrome, abatement of chemotherapy side effects and pain management for cancer patients are just a few of the many conditions which patients may choose to treat with medical cannabis.
As awareness and use of cannabis-based products has increased, legalization has allowed public health agencies and members of the public to question the quality, purity and potency of these products. In response, states have instituted requirements for testing cannabis-based products to varying degrees. But people are asking, “Why should we have to test cannabis products?”
Cannabis has long been considered a natural product with few health hazards. In reality, the production of cannabis and associated products may include the use of pesticides, solvents and the risk of microbial contamination. For individuals whose health is compromised in some way (patients undergoing chemotherapy, for example), these hazards may pose significant health risks.
The most immediate potential health risks of cannabis products are bacteria, mold and fungus present at levels that can cause microbial infections. Although bacteria live everywhere including within us, pathogens like Salmonella and E.coli, can quickly infect a healthy person. These bacteria have a much higher potential for affecting a person whose immune system is compromised. Microbial testing ensures that the product they are purchasing cannot cause an infection that would worsen their health.
Many cannabis growers, like other types of farmers, use pesticides to control microbial, insect and fungus infestations at their facilities. Because the US Drug Enforcement Agency (DEA) classifies cannabis as a schedule 1 controlled substance, the Environmental Protection Agency (EPA) and the Food and Drug Administration (FDA) cannot issue guidance on the use of pesticides on cannabis plants. However, state public health and agricultural agencies in jurisdictions where cannabis is legal have begun to regulate the type and amount of pesticides that can be applied to cannabis.
For medical cannabis patients, the fewer chemicals used, the better. Pesticide risk potential has yet to be fully understood because little scientific research has been performed. Thus, keeping the use of pesticides to a minimum and ensuring that approved pesticides are used – which requires analytical testing – is an essential part of any regulated program.
Another issue is potency. All cannabis plants and products aren’t the same, which means that potency varies widely. Without knowing the potency of the products, a person may unwittingly take too much or too little. Prescription and over-the-counter medications have dosage information on the label so patients know how much to take. This is a mandatory practice for medicinal products. Testing for potency and adding this information to the cannabis product label gives patients vital information on what they are purchasing and how much of a product they should consume or use. Without this, they are flying blind in the treatment of their illness or condition. Further, many states require that cannabis products contain a maximum amount of cannabinoids and this must be verified with testing. Whatever the state requirements, it is imperative that patients know the level of active ingredients in cannabis products and can count on their homogeneity.
These concerns aren’t limited to consumption of the plant. Patients using cannabis extracts and oils need to be aware that the active ingredients (cannabinoids and terpenes) are extracted utilizing a variety of techniques including the use of solvents such as propane, butane, acetone and alcohol. Exposure to solvents can cause a variety of illnesses that can negatively impact a patient. Though many states have set rigorous requirements for acceptable levels of residual solvents, cannabis products need to be tested to ensure that they are at a safe concentration. As more products are tested for solvents, many grow facilities and manufacturers have begun to develop alternative extraction techniques that do not use solvents, thus avoiding this issue entirely.
More patient and industry advocacy groups are demanding testing as awareness of potential hazards grows. To ensure their products have been tested, patients should ask dispensaries and manufacturers for detailed testing information that may not be included on product labels. This will help to intensify the push for safer and more effective cannabis-based products for the treatment of their illness or condition.
Both public health agencies and the cannabis industry want competent accredited laboratories to perform the testing with standardized methodologies.
The cannabis industry is responding with new and improved growing and extraction techniques and greater involvement in the regulatory process, and public health agencies are responding with new testing requirements, product recalls and by taking a consensus approach to regulation involving all cannabis industry stakeholder groups including consumer advocates.
“A Clearheaded Case for Cannabis Testing.” Lab Matters, Winter 2016
“Guidance for State Medical Cannabis Testing Programs.” APHL, May 2016
This post wasn’t written by an APHL staff member and the views expressed in the post are those of the guest author and do not necessarily reflect the views or opinions of APHL. If the post contains an evaluation or opinion about a product or service, this represents the guest blogger’s personal belief and does not represent APHL’s endorsement or critique.
Do you suppose Steven Pinker’s broadside against professional bioethics oversight of CRISPR and other forms of gene editing–Pinker’s command to bioethics was brutally inflexible: “Get out of the way”–will change bioethics for the better? Or gene editing, for that matter? … Continue reading
The post Pinker’s gene editing rant ignored most bioethics issues; debunking stoner Shakespeare appeared first on PLOS Blogs Network.
Do 12-step programs for addiction treatment work? Are 12-step programs like Alcoholics Anonymous and Narcotics Anonymous effective treatments for addiction? That long-time dispute has just popped up again, prompted mostly by an Atlantic article with the click-worthy title “The Irrationality … Continue reading
The post Do AA and other 12-step programs work? Does breastfeeding raise IQ? appeared first on PLOS Blogs Network.
Posted by 12-step programs, ACA, affordable care act, Alcoholics Anonymous, breast milk, breastfeeding, Cannabis, health care, intelligence, IQ, marijuana, media criticism, medical journalism, medical writing, Narcotics Anonymous, Obamacare, On Science Blogs, Patient Protection and Affordable Care Act, pot, psychology, Research, science blogging, Science Journalism, Science Writing, womenin
Artist Dalya Luttwak takes hard steel and transforms it into the sinuous shapes of roots. For a recent show at the Greater Reston Art Center in Virginia, Luttwak chose as one of her subjects the root system of Cannabis Sativa. Cannabis, a plant of many uses, which evokes strong and complex responses and touches on so many areas of our culture – industrial, medical, recreational, and criminal – is an irresistible subject for art.
Working in a combination of gilded and blackened steel, the artist “sought the “golden balance” arising from the combination of vertical and horizontal black roots, and existing between the different elements of the Cannabis plant and their nutritious, medical, and psychedelic uses.”
Luttwak, who was born in Israel and now works in the US, says that her work tries to “uncover the hidden beauty of roots, exploring the relationship between what grows above the ground and the invisible parts below of various root systems. My sculptures reveal what nature prefers to conceal. My wish is to uncover and discover roots even when they are hidden, indeed especially when they are hidden.” (source)
Beyond the secrets of plant life, however, this sculpture, and many of Luttwak’s other works, strongly evoke the brain and nervous system. Seeing the roots of the Cannabis Sativa as a metaphor for the paths of chemical stimulation or even of our tangled attitudes to drug-taking, elevate and deepen our response to this deceptively simple art.
You can see more of Dalya Luttwak’s work on her website.
Filed under: The Art of Science Tagged: cannabis, sciart, Sculpture
Still going to pot The Republicans won big last Tuesday. But so did marijuana. Here’s a summary, from Conor Friedersdorf at The Atlantic: “Oregon and Alaska just became the third and fourth states to legalize the drug. Washington, D.C., … Continue reading
The post Election: marijuana, climate change, abortion, Obamacare, soda tax, GMOs appeared first on PLOS Blogs Network.
Posted by ACA, affordable care act, Cannabis, climate change, climate change denial, contraception, genetic modification, genetically modified organisms, Genome, Genomics, global warming, GMO, health care, marijuana, medical marijuana, Obamacare, On Science Blogs, Patient Protection and Affordable Care Act, Politics, pot, Research, united states, weed, womenin
Legal marijuana and cannabis research, Google X health project, Retraction Watch, regulating genetic research
Legalizing cannabis in order to legalize cannabis research?
The New York Times has been running a series of editorials and commentaries and blog posts backing legal marijuana. Even although it’s been clear for some time that’s where we’re headed, …
Posted by aging, Baseline Study, Cannabis, Craig Venter, CRISPR, gene drives, gene editing, genetic engineering, Genetic Literacy Project, Genome, Genomics, GMO, Google X, health care, herbal medicine, media criticism, medical marijuana, On Science Blogs, Politics, pot, regulation, Research, Retraction Watch, science blogging, Science Journalism, united states, weedin
Lab safety, smallpox and more virulent flu, marijuana benefits, plus headless, heedless, and clueless at Science
Lab safety is even worse than you thought
The best single blog source for keeping up with the current smallpox-anthrax-flu-lab safety fiasco is Maryn McKenna’s Superbug, one of the Wired blogs. Some recent posts:
About the cache of old vials …
Posted by Anthrax, Asia, biohazard, bioweapons, Cannabis, CDC, climate change denial, Colorado, flu, Genetic Literacy Project, Genome, Genomics, health care, influenza, lab safety, marijuana, media criticism, medical marijuana, medical writing, microbes, National Institute on Drug Abuse, National Science Advisory Board for Biosecurity, NIDA, On Science Blogs, Politics, pot, Research, Science Writing, sexual harassment, smallpox, variola, weed, womenin